Zobrazeno 1 - 10
of 15
pro vyhledávání: '"N Yu, Sokolov"'
Autor:
N. E. Kushlinskii, O. V. Kovaleva, Yu. B. Kuzmin, E. V. Samoilova, P. L. Prishchep, E. S. Gershtein, S. R. Varfolomeeva, D. V. Rogozhin, N. Yu. Sokolov, K. A. Borzov, E. A. Sushentsov, A. K. Valiev, I. S. Stilidy
Publikováno v:
Успехи молекулярной онкологии, Vol 10, Iss 2, Pp 100-107 (2023)
Introduction. Enzyme-linked immunosorbent assay of biochemical markers is one of the most important methods for diagnosing tumors. One of these markers is an inducer of expression of matrix metalloproteases EMMPRIN/CD147. Changes in its expression ar
Externí odkaz:
https://doaj.org/article/e5a5401085ba4e098a71e484a7840114
Autor:
A. V. Shabunin, D. N. Grekov, Z. A. Bagateliya, V. M. Kulushev, N. Yu. Sokolov, A. G. Minenkova, S. S. Lebedev, M. S. Lebedko
Publikováno v:
Pelvic Surgery and Oncology. 12:52-59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a1232b0a46187d404de0c88083e5248
https://doi.org/10.17650/2686-9594-2022-12-4-52-59
https://doi.org/10.17650/2686-9594-2022-12-4-52-59
Publikováno v:
Russian Journal of Biotherapy. 21:10-18
The interaction of the innate and adaptive immunity is necessary for the immune response to SARS-CoV-2. The innate immunity serves as the body’s first line of defense in a rapid and non-specific manner. The adaptive immune reaction proceeds more sl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d01dfe753c9a5b53a4327da227b95601
https://doi.org/10.17650/1726-9784-2022-21-2-10-18
https://doi.org/10.17650/1726-9784-2022-21-2-10-18
Autor:
Elena Sergeyevna Gershtein, E. A. Korotkova, I. K. Vorotnikov, N. Yu. Sokolov, V. D. Ermilova, A. S. Mochalova, N. E. Kushlinskii
Publikováno v:
Russian Clinical Laboratory Diagnostics. 67:76-80
Results of enzyme-linked immunosorbent assay of the soluble forms of PD-1/PD-L immune checkpoint receptor and ligand (sPD-1 and sPD-L1) in pretreatment blood serum of 88 breast cancer patients at various disease stages aged 30-83 years are presented.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::139157e2e470a95575b42476842e28f5
https://doi.org/10.51620/0869-2084-2022-67-2-76-80
https://doi.org/10.51620/0869-2084-2022-67-2-76-80
Autor:
I. Zh. Shubina, A. N. Gritsay, L. T. Mamedova, N. Yu. Sokolov, S. A. Kuznetsov, M. V. Kiselevskiy, N. I. Lazareva, V. V. Kuznetsov, K. S. Titov, A. P. Nikolayev
Publikováno v:
Опухоли женской репродуктивной системы, Vol 0, Iss 3-4, Pp 110-113 (2014)
In the last decade, accumulated evidence in favor of that ovarian cancer is an immunogenic tumor. Immunotherapy is aimed at stimulating the innate and adaptive immunity, may cause an effective response in patients with ovarian cancer. Various approac
Externí odkaz:
https://doaj.org/article/51e7701c947542b0be9c424fe49bca4e
Autor:
N. E. Kushlinskii, O V Kovaleva, E A Korotkova, N Yu Sokolov, I V Tereshkina, D. N. Kushlinsky, P A Podlesnaya, A N Gratchev, T P Belova, S V Zinoviev, Dmitry Kudlay
Publikováno v:
Russian Clinical Laboratory Diagnostics. 66:80-86
The data of a complex immunoassay comparative study of the content of soluble forms of sPD-1, sPD-L1, sNKG2D, sNKG2DL1, sB7-H3 and sHLA-G in the blood plasma of 75 patients with epithelial ovarian cancer and 20 healthy donors of the control group are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb1e394ba4eb15244f0fa02d97f86df9
https://doi.org/10.51620/0869-2084-2021-66-2-80-86
https://doi.org/10.51620/0869-2084-2021-66-2-80-86
Autor:
I.V. Boulitcheva, V V Maslennikov, E A Korotkova, N. E. Kushlinskii, N Yu Sokolov, V V Delektorskaya, E. S. Gershtein, O V Kovaleva, M A Rashidova, A N Gratchev, Z Z Mamedli
Publikováno v:
Doklady Biochemistry and Biophysics. 497:66-70
Due to the low efficiency of immunotherapy for colorectal cancer (CRC), it is extremely promising and relevant to study the mechanisms of immunosuppression. In this work, a comprehensive study of the expression of soluble and tissue forms of PD-1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3de2ea5b91fb7073385b1966c616452b
https://doi.org/10.1134/s1607672921020095
https://doi.org/10.1134/s1607672921020095
Autor:
Yu S Timofeev, A A Alferov, M M Efimova, O T Khvan, M Yu Shchupak, E A Korotkova, N Yu Sokolov, N. E. Kushlinskii, Yu B Kuzmin, E A Sushentsov, I. V. Boulytcheva, I N Kuznetsov, M. D. Aliev, E. S. Gershtein, E R Musaev, A V Bondarev
Publikováno v:
Russian Clinical Laboratory Diagnostics. 65:669-675
Results of ELISA investigation of the pretreatment sPD-1 and sPD-L1 content in blood serum of 133 bone neoplasms patients aged 6-70 years and 57 practically healthy control persons aged 12-70 years are described. In 14 patients the neoplasms were of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75f5b134510441bf49f44b92db18e976
https://doi.org/10.18821/0869-2084-2020-65-11-669-675
https://doi.org/10.18821/0869-2084-2020-65-11-669-675
Autor:
E. S. Gershtein, S B Polikarpova, A A Dzampaev, M M Efimova, N. E. Kushlinskii, M Yu Shchupak, Yu S Timofeev, E A Sushentsov, M. D. Aliev, N Yu Sokolov, A A Alferov, I. V. Bulycheva, E R Musaev, A V Bondarev
Publikováno v:
Bulletin of Experimental Biology and Medicine. 170:64-68
The levels of sPD-1 and sPD-L1 were analyzed in blood serum of 132 patients (age 14-70 years) with primary bone tumors: osteosarcoma (N=39), chondrosarcoma (N=42), Ewing sarcoma (N=9), chordoma (N=12), giant-cell bone tumor (GCBT) (N=16), benign neop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e61348aebc6ee4ef609d17dbc656afc5
https://doi.org/10.1007/s10517-020-05005-2
https://doi.org/10.1007/s10517-020-05005-2
Autor:
N. E. Kushlinskii, N.A. Ognerubov, N Yu Sokolov, A A Alferov, E S Gershtein, E A Korotkova, E I Karamysheva, Ivan Stilidi, M M Kontorshchikov, V L Chang
Publikováno v:
Klinicheskaia laboratornaia diagnostika. 66(3)
Analysis of long-term treatment results of 101 primary gastric cancer patients at various stages of the tumor process followed during 1 - 41 months (median - 6,4 months) from the onset of specific treatment are presented depending on the levels of so
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::991b5e4e5070d5ae39725ac30cf67363
https://pubmed.ncbi.nlm.nih.gov/33793112
https://pubmed.ncbi.nlm.nih.gov/33793112